摘要
目的探讨血管内皮生长因子受体(FLK-1)、肺耐药蛋白(lung resistance protein,LRP)及半胱氨酸天冬氨酸特异性蛋白酶(Caspase-3)中的表达及临床意义。方法采用免疫组织化学(SP)法检测FLK-1、LRP、Caspase-3在63例肺癌和12例正常肺组织中的表达。结果①63例肺癌中FLK-1、LRP和Caspase-3阳性表达率分别为52.3%、60.3%和61.9%。②FLK-1的表达水平在肺癌组织不同临床TNM分期以及有无淋巴结转移间比较差异均有显著性(P<0.05),在不同病理分级和病理类型间比较差异无显著性(P>0.05)。③LRP的表达水平在肺癌组织不同病理分级、病理类型以及有无淋巴结转移间比较差异均有显著性(P<0.05),在不同临床TNM分期间比较差异无显著性(P>0.05)。④Caspase-3表达水平在不同病理分级以及淋巴结转移间比较差异均有显著性(P<0.05),在非小细胞与小细胞肺癌之间差异无显著性,但在鳞癌中的阳性表达率显著高于腺癌,在不同临床TNM分期间比较差异无显著性(P>0.05)。⑤FLK-1、LRP、Caspase-3三者之间无明显相关性。结论检测FLK-1、LRP、Caspase-3的表达水平,对肺癌的诊治及判断预后有重要意义。
[Objective ] To study the clinical significance of the expression of blood vessel bast growth factor acceptor（FLK-1）, lung resistance protein （LRP）, cystelnyl aspartate specific proteinase （Caspase-3） in patients with lung cancer. [Methods] Immuno-histochemical menthod （SP） was used to detect the expression of FLK-1, LRP, Caspase-3 in 63 lung cancer tissues and 12 normal lung tissues. [Results] ①The positive expression rates of FLK-1 ,LRP and Caspase-3 were 52.3%, 50.3% and 61.9%, respectively in the 63 lung cancer. ②Significant difference of the expression level of FLK-1 in lung cancer was found between different clinical TNM stages and lymph noge involvement （P 〈0.05）, and there was no significant difference on expression level of FLK-1 in lung cancer between different pathological grades and pathological types （P〉0.05）. ③Significant difference on expression level of LRP in lung cancer was found between different pathological grades pathological types and lymph noge involvement （P 〈 0.05）. ④Significant difference on expression level of Caspase-3 in lung cancer was found between different pathological grades and lymph noge involvement （P 〈0.05）. There was no significant difference on expression level of Caspase-3 between NSCLC and SCLC. The positive expression rates of Caspase-3 in squamous carcinomas was higher than that in adenocarcinomas. ⑤here was no correlation between the expression of FLK-1, LRP and Caspase-3. [Conclusion] Examination of expression levels of FLK-1, LRP and Caspase-3 are of clinical significance in diagnosis, treatment and prognosis of lung cancer.
出处
《中国医学工程》
2007年第11期876-880,共5页
China Medical Engineering
